HomeComparePTEEF vs ABBV

PTEEF vs ABBV: Dividend Comparison 2026

PTEEF yields 5000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PTEEF wins by $62217131802825.25M in total portfolio value
10 years
PTEEF
PTEEF
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full PTEEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PTEEF vs ABBV

📍 PTEEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTEEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTEEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTEEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTEEF
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PTEEF beats the other by $50,882,683,244,271,450,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTEEF + ABBV for your $10,000?

PTEEF: 50%ABBV: 50%
100% ABBV50/50100% PTEEF
Portfolio after 10yr
$31108565901412.73M
Annual income
$29,930,990,143,689,118,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PTEEF
No analyst data
Altman Z
1.7
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTEEF buys
0
ABBV buys
0
No recent congressional trades found for PTEEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTEEFABBV
Forward yield5000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$62217131802825.35M$102.3K
Annual income after 10y$59,861,980,287,378,210,000.00$24,771.77
Total dividends collected$62057786341622.61M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PTEEF vs ABBV ($10,000, DRIP)

YearPTEEF PortfolioPTEEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$510,700$500,000.00$11,550$430.00+$499.1KPTEEF
2$24,410,935$23,864,485.98$13,472$627.96+$24.40MPTEEF
3$1,092,192,501$1,066,072,800.30$15,906$926.08+$1092.18MPTEEF
4$45,746,366,951$44,577,720,975.17$19,071$1,382.55+$45746.35MPTEEF
5$1,793,932,828,410$1,744,984,215,772.56$23,302$2,095.81+$1793932.81MPTEEF
6$65,871,973,805,320$63,952,465,678,921.49$29,150$3,237.93+$65871973.78MPTEEF
7$2,265,146,887,602,700$2,194,663,875,631,007.20$37,536$5,121.41+$2265146887.57MPTEEF
8$72,954,689,148,998,180$70,530,981,979,263,280.00$50,079$8,338.38+$72954689148.95MPTEEF
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$69,753$14,065.80+$2201076182660.81MPTEEF
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$102,337$24,771.77+$62217131802825.25MPTEEF

PTEEF vs ABBV: Complete Analysis 2026

PTEEFStock

Plaintree Systems Inc. designs, develops, manufactures, markets, and supports electronic products and specialty structural products in Canada, the United States, and internationally. The company manufactures avionic components for various applications, including aircraft antiskid braking, aircraft indicators, solenoids, and permanent magnet alternators; and operates as a design/build manufacturer of steel, aluminum, and stainless-steel specialty structures comprising commercial domes, free form structures, barrel vaults, space frames, and industrial dome coverings. It also provides super-alloys for the aircraft and helicopter markets; designs and manufactures custom hydraulic and pneumatic valves and cylinders for industrial, automation, and oil and gas markets; and manufactures kitchen appliances. Plaintree Systems Inc. was founded in 1988 and is headquartered in Arnprior, Canada.

Full PTEEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PTEEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTEEF vs SCHDPTEEF vs JEPIPTEEF vs OPTEEF vs KOPTEEF vs MAINPTEEF vs JNJPTEEF vs MRKPTEEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.